Profile data is unavailable for this security.
About the company
Cipla Limited is an India-based company, which is primarily engaged in the business of pharmaceuticals. The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The Company's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa, and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 47 manufacturing sites.
- Revenue in USD (TTM)277.10m
- Net income in USD48.87m
- Incorporated1935
- Employees27.76k
- LocationCipla LtdMumbai CentralMUMBAI 400013IndiaIND
- Phone+91 2 224826000
- Fax+91 2 224826120
- Websitehttps://www.cipla.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intra-Cellular Therapies Inc | 564.53m | -84.30m | 7.87bn | 610.00 | -- | 6.87 | -- | 13.94 | -0.8629 | -0.8629 | 5.75 | 10.84 | 0.5551 | 1.33 | 4.67 | 925,452.40 | -8.29 | -38.27 | -9.47 | -42.77 | 92.72 | -- | -14.93 | -128.42 | 7.69 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Roivant Sciences Ltd | 158.30m | 4.74bn | 8.79bn | 845.00 | 2.13 | 1.62 | 1.89 | 55.50 | 5.57 | 5.57 | 0.1979 | 7.35 | 0.0367 | 0.8018 | 2.71 | 187,340.80 | 106.95 | -- | 126.66 | -- | 90.32 | -- | 2,916.27 | -- | 27.75 | -- | 0.052 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Catalent Inc | 4.14bn | -1.18bn | 10.76bn | 17.80k | -- | 2.96 | -- | 2.60 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | 0.0154 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Incyte Corp | 3.86bn | 97.30m | 12.35bn | 2.52k | 181.38 | 4.10 | 66.98 | 3.20 | 0.3536 | 0.3536 | 17.18 | 15.64 | 0.7097 | 3.58 | 5.60 | 1,528,136.00 | 1.79 | 9.07 | 2.31 | 11.02 | 93.66 | 94.97 | 2.52 | 13.68 | 1.84 | -- | 0.0108 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Viatris Inc | 15.24bn | -646.50m | 14.04bn | 38.00k | -- | 0.7189 | 6.51 | 0.921 | -0.5433 | -0.5433 | 12.68 | 16.36 | 0.3242 | 2.30 | 5.25 | 401,031.60 | -1.38 | 0.0887 | -1.62 | 0.1061 | 42.78 | 40.29 | -4.24 | 0.2891 | 1.02 | 2.48 | 0.4668 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Cipla Ltd (ADR) | 277.10m | 48.87m | 15.15bn | 27.76k | -- | -- | 273.27 | 54.67 | 0.0433 | 0.0433 | -- | 0.6182 | -- | -- | -- | 46,696.95 | -- | -- | -- | -- | 47.90 | -- | 17.64 | -- | 1.29 | 57.90 | 0.1115 | -- | 19.29 | -- | 33.56 | -- | -- | -- |
Royalty Pharma plc | 2.24bn | 673.24m | 16.84bn | 89.00 | 18.74 | 1.95 | 20.06 | 7.53 | 1.50 | 1.50 | 3.74 | 14.42 | 0.1287 | -- | 76.10 | 25,141,870.00 | 5.92 | 9.57 | 7.77 | 12.42 | -- | -- | 46.02 | 67.80 | -- | -- | 0.4381 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
Biomarin Pharmaceutical Inc | 2.59bn | 256.59m | 17.14bn | 3.40k | 67.86 | 3.24 | 47.22 | 6.62 | 1.33 | 1.33 | 13.28 | 27.77 | 0.3798 | 0.4778 | 3.98 | 761,069.70 | 3.76 | 0.7116 | 4.29 | 0.8079 | 80.07 | 76.30 | 9.91 | 2.05 | 1.95 | -- | 0.1708 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |